title: Crystallization-induced diastereoselection: asymmetric synthesis of substance P inhibitors.
abstract: A novel three-component condensation followed by a crystallization-induced asymmetric transformation is used to build this key substance P inhibitor intermediate in a short synthetic sequence.
authors.affiliation: Department of Process Research, Merck Research Laboratories, P.O. Box 2000, Rahway, New Jersey 07065, USA. philip_pye@merck.com
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Pye
authors.forename: Kai
authors.initials: K
authors.lastname: Rossen
authors.forename: Steven A
authors.initials: SA
authors.lastname: Weissman
authors.forename: Ashok
authors.initials: A
authors.lastname: Maliakal
authors.forename: Robert A
authors.initials: RA
authors.lastname: Reamer
authors.forename: Richard
authors.initials: R
authors.lastname: Ball
authors.forename: Nancy N
authors.initials: NN
authors.lastname: Tsou
authors.forename: R P
authors.initials: RP
authors.lastname: Volante
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Reider
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000138:chemical synthesis*; D003460:Crystallization; D006801:Humans; D006900:Hydroxylation; D015394:Molecular Structure; D009025:Morpholines / Q000138:chemical synthesis*; D013237:Stereoisomerism; D013373:Substance P / Q000037:antagonists & inhibitors*; D014230:Triazoles / Q000138:chemical synthesis*
chemical_list: C473334:2-(4-fluorophenyl)-1-(3-oxo-(2H,4H)-1,2,4-triazol-5-ylmethyl)-3-(1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)morpholine; D000928:Antidepressive Agents; D009025:Morpholines; D014230:Triazoles; D013373:Substance P